View Future GrowthChemoMetec 과거 순이익 실적과거 기준 점검 3/6ChemoMetec은 연평균 11.1%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 3.6% 증가했습니다. 매출은 연평균 10%의 비율로 증가했습니다. ChemoMetec의 자기자본이익률은 27.1%이고 순이익률은 35.9%입니다.핵심 정보11.13%순이익 성장률11.13%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률10.00%자기자본이익률27.13%순이익률35.90%다음 순이익 업데이트10 Sep 2026최근 과거 실적 업데이트Reported Earnings • Feb 06First half 2026 earnings released: EPS: kr.5.40 (vs kr.5.94 in 1H 2025)First half 2026 results: EPS: kr.5.40 (down from kr.5.94 in 1H 2025). Revenue: kr.249.0m (down 1.0% from 1H 2025). Net income: kr.94.0m (down 9.1% from 1H 2025). Profit margin: 38% (down from 41% in 1H 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 12Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: kr.10.71 (up from kr.7.83 in FY 2024). Revenue: kr.495.6m (up 22% from FY 2024). Net income: kr.186.4m (up 37% from FY 2024). Profit margin: 38% (up from 33% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.Reported Earnings • Feb 07First half 2025 earnings released: EPS: kr.5.94 (vs kr.4.05 in 1H 2024)First half 2025 results: EPS: kr.5.94 (up from kr.4.05 in 1H 2024). Revenue: kr.251.5m (up 26% from 1H 2024). Net income: kr.103.4m (up 47% from 1H 2024). Profit margin: 41% (up from 35% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.분석 기사 • Sep 18We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish EarningsDespite ChemoMetec A/S' ( CPH:CHEMM ) recent earnings report having lackluster headline numbers, the market responded...Reported Earnings • Sep 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025모든 업데이트 보기Recent updates공시 • May 16ChemoMetec A/S, Annual General Meeting, Oct 08, 2026ChemoMetec A/S, Annual General Meeting, Oct 08, 2026.Price Target Changed • May 11Price target decreased by 15% to kr.546Down from kr.640, the current price target is an average from 4 analysts. New target price is 74% above last closing price of kr.315. Stock is down 37% over the past year. The company is forecast to post earnings per share of kr.11.28 for next year compared to kr.10.71 last year.공시 • May 06Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services.Buy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 50% to kr.345. The fair value is estimated to be kr.432, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 59% in the next 2 years.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr.350, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 1.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.433 per share.공시 • Mar 26ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million.Price Target Changed • Mar 26Price target decreased by 10% to kr.691Down from kr.771, the current price target is an average from 4 analysts. New target price is 131% above last closing price of kr.299. Stock is down 41% over the past year. The company is forecast to post earnings per share of kr.11.90 for next year compared to kr.10.71 last year.New Risk • Mar 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 43%After last week's 43% share price decline to kr.237, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years.Buy Or Sell Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 44% to kr.416. The fair value is estimated to be kr.525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 83% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to kr.394, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 16x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.460 per share.분석 기사 • Feb 08ChemoMetec A/S' (CPH:CHEMM) 40% Cheaper Price Remains In Tune With EarningsThe ChemoMetec A/S ( CPH:CHEMM ) share price has fared very poorly over the last month, falling by a substantial 40...분석 기사 • Feb 07ChemoMetec A/S (CPH:CHEMM) Just Reported Earnings, And Analysts Cut Their Target PriceThere's been a major selloff in ChemoMetec A/S ( CPH:CHEMM ) shares in the week since it released its interim report...Price Target Changed • Feb 06Price target decreased by 7.0% to kr.809Down from kr.870, the current price target is an average from 4 analysts. New target price is 87% above last closing price of kr.433. Stock is down 23% over the past year. The company is forecast to post earnings per share of kr.12.73 for next year compared to kr.10.71 last year.Reported Earnings • Feb 06First half 2026 earnings released: EPS: kr.5.40 (vs kr.5.94 in 1H 2025)First half 2026 results: EPS: kr.5.40 (down from kr.5.94 in 1H 2025). Revenue: kr.249.0m (down 1.0% from 1H 2025). Net income: kr.94.0m (down 9.1% from 1H 2025). Profit margin: 38% (down from 41% in 1H 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Feb 06Chemometec A/S Maintains Earnings Guidance for the Year 2025ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range.Price Target Changed • Nov 12Price target increased by 9.7% to kr.870Up from kr.793, the current price target is an average from 4 analysts. New target price is 12% above last closing price of kr.779. Stock is up 66% over the past year. The company is forecast to post earnings per share of kr.13.80 for next year compared to kr.10.71 last year.Recent Insider Transactions • Nov 10Chief Executive Officer recently bought kr.1.0m worth of stockOn the 7th of November, Martin Behrens bought around 1k shares on-market at roughly kr.684 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months.분석 기사 • Oct 31Earnings Tell The Story For ChemoMetec A/S (CPH:CHEMM) As Its Stock Soars 27%Despite an already strong run, ChemoMetec A/S ( CPH:CHEMM ) shares have been powering on, with a gain of 27% in the...공시 • Oct 28ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26.Price Target Changed • Oct 27Price target increased by 17% to kr.793Up from kr.677, the current price target is an average from 3 analysts. New target price is 9.4% above last closing price of kr.725. Stock is up 78% over the past year. The company is forecast to post earnings per share of kr.13.05 for next year compared to kr.10.71 last year.Buy Or Sell Opportunity • Oct 27Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to kr.725. The fair value is estimated to be kr.585, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.공시 • Oct 10ChemoMetec A/S Approves to Distribute DividendChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1.Declared Dividend • Oct 03Dividend increased to kr.7.00Dividend of kr.7.00 is 75% higher than last year. Ex-date: 10th October 2025 Payment date: 14th October 2025 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (85% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Buy Or Sell Opportunity • Oct 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to kr.654. The fair value is estimated to be kr.545, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.분석 기사 • Oct 01Calculating The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)Key Insights The projected fair value for ChemoMetec is kr.554 based on 2 Stage Free Cash Flow to Equity Current share...Valuation Update With 7 Day Price Move • Sep 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to kr.653, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 15x in the Life Sciences industry in Europe. Total returns to shareholders of 8.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.553 per share.공시 • Sep 18ChemoMetec A/S, Annual General Meeting, Oct 09, 2025ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark분석 기사 • Sep 16ChemoMetec A/S (CPH:CHEMM) Looks Just Right With A 26% Price JumpChemoMetec A/S ( CPH:CHEMM ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Price Target Changed • Sep 15Price target increased by 8.6% to kr.677Up from kr.623, the current price target is an average from 3 analysts. New target price is 7.2% above last closing price of kr.632. Stock is up 52% over the past year. The company is forecast to post earnings per share of kr.13.07 for next year compared to kr.10.71 last year.분석 기사 • Sep 15ChemoMetec A/S (CPH:CHEMM) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?It's been a pretty great week for ChemoMetec A/S ( CPH:CHEMM ) shareholders, with its shares surging 12% to kr.610 in...공시 • Sep 13+ 3 more updatesChemometec A/S Provides Earnings Guidance for the Financial Year 2025/26ChemoMetec A/S provided earnings guidance for the financial year 2025/26. For the period, ChemoMetec expects revenue in the range of DKK 545 million-565 million (2024/25: DKK 495.6 million).Reported Earnings • Sep 12Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: kr.10.71 (up from kr.7.83 in FY 2024). Revenue: kr.495.6m (up 22% from FY 2024). Net income: kr.186.4m (up 37% from FY 2024). Profit margin: 38% (up from 33% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.Buy Or Sell Opportunity • Sep 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.1% to kr.562. The fair value is estimated to be kr.466, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 48% in the next 2 years.분석 기사 • Jul 07ChemoMetec A/S' (CPH:CHEMM) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 15x, you may consider...New Risk • Jun 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Danish stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Jun 11At kr.554, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?While ChemoMetec A/S ( CPH:CHEMM ) might not have the largest market cap around , it led the CPSE gainers with a...분석 기사 • Apr 06Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is UnlikelyWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to kr.424, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.313 per share.분석 기사 • Feb 08ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent ResultsAs you might know, ChemoMetec A/S ( CPH:CHEMM ) recently reported its half-year numbers. Overall the results were a...Reported Earnings • Feb 07First half 2025 earnings released: EPS: kr.5.94 (vs kr.4.05 in 1H 2024)First half 2025 results: EPS: kr.5.94 (up from kr.4.05 in 1H 2024). Revenue: kr.251.5m (up 26% from 1H 2024). Net income: kr.103.4m (up 47% from 1H 2024). Profit margin: 41% (up from 35% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 06Price target increased by 12% to kr.613Up from kr.545, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of kr.568. Stock is up 18% over the past year. The company is forecast to post earnings per share of kr.11.51 for next year compared to kr.7.83 last year.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr.560, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.351 per share.공시 • Jan 10Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial YearChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance.분석 기사 • Dec 12What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?ChemoMetec A/S ( CPH:CHEMM ), might not be a large cap stock, but it saw a significant share price rise of 42% in the...공시 • Dec 04ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance.Recent Insider Transactions • Nov 12Deputy Chairman & Senior Advisor recently bought kr.3.2m worth of stockOn the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly kr.456 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of kr.3.5m worth in shares.Price Target Changed • Nov 11Price target increased by 15% to kr.505Up from kr.438, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of kr.504. Stock is up 55% over the past year. The company is forecast to post earnings per share of kr.10.06 for next year compared to kr.7.83 last year.Major Estimate Revision • Nov 10Consensus EPS estimates increase by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from kr.9.26 to kr.10.24. Revenue forecast steady at kr.460.2m. Net income forecast to grow 31% next year vs 29% growth forecast for Life Sciences industry in Denmark. Consensus price target of kr.438 unchanged from last update. Share price rose 19% to kr.484 over the past week.분석 기사 • Nov 09ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than ExpectedThe ChemoMetec A/S ( CPH:CHEMM ) share price has done very well over the last month, posting an excellent gain of 32...New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (21% accrual ratio).공시 • Nov 08ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million.Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr.484, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.266 per share.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Oct 23ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date. ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024.공시 • Oct 17ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance.Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to kr.438, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.239 per share.공시 • Oct 11ChemoMetec A/S Approves DividendChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1.Upcoming Dividend • Oct 04Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of Danish dividend payers (5.8%). Higher than average of industry peers (0.7%).공시 • Sep 21ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. The transaction is subject to consummation of due diligence investigation.분석 기사 • Sep 18We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish EarningsDespite ChemoMetec A/S' ( CPH:CHEMM ) recent earnings report having lackluster headline numbers, the market responded...Declared Dividend • Sep 15Dividend of kr.4.00 announcedShareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Price Target Changed • Sep 13Price target increased by 8.0% to kr.473Up from kr.438, the current price target is an average from 2 analysts. New target price is 10.0% above last closing price of kr.430. Stock is up 20% over the past year. The company is forecast to post earnings per share of kr.9.05 for next year compared to kr.7.83 last year.Reported Earnings • Sep 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.공시 • Sep 12ChemoMetec A/S provides earnings guidance for the year 2024/25ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year.Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr.429, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.261 per share.공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025분석 기사 • Jul 29What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling YouThe ChemoMetec A/S ( CPH:CHEMM ) share price has done very well over the last month, posting an excellent gain of 27...분석 기사 • Jul 29Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%ChemoMetec A/S ( CPH:CHEMM ) shareholders have had their patience rewarded with a 27% share price jump in the last...Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr.352, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.238 per share.분석 기사 • Jul 03What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?ChemoMetec A/S ( CPH:CHEMM ), is not the largest company out there, but it received a lot of attention from a...공시 • May 25ChemoMetec A/S Announces CFO ChangesThe board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec.Recent Insider Transactions • May 16Independent Director recently bought kr.450k worth of stockOn the 13th of May, Peter Reich bought around 1k shares on-market at roughly kr.310 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr.751k more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • May 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr.366, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.220 per share.Buy Or Sell Opportunity • Apr 26Now 20% overvaluedOver the last 90 days, the stock has fallen 30% to kr.287. The fair value is estimated to be kr.238, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.Price Target Changed • Apr 16Price target increased by 14% to kr.513Up from kr.448, the current price target is an average from 2 analysts. New target price is 65% above last closing price of kr.310. Stock is down 11% over the past year. The company is forecast to post earnings per share of kr.7.69 for next year compared to kr.10.27 last year.Buy Or Sell Opportunity • Apr 15Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to kr.298. The fair value is estimated to be kr.246, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 33% in the next 2 years.분석 기사 • Apr 15Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%ChemoMetec A/S ( CPH:CHEMM ) shareholders won't be pleased to see that the share price has had a very rough month...공시 • Apr 13ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to kr.310, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.246 per share.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr.444, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.245 per share.공시 • Mar 13ChemoMetec A/S Announces CEO ChangesThe Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec.분석 기사 • Mar 01What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling YouDespite an already strong run, ChemoMetec A/S ( CPH:CHEMM ) shares have been powering on, with a gain of 30% in the...분석 기사 • Mar 01What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?ChemoMetec A/S ( CPH:CHEMM ), might not be a large cap stock, but it led the CPSE gainers with a relatively large price...Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 30%After last week's 30% share price gain to kr.462, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.246 per share.분석 기사 • Feb 08Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsA week ago, ChemoMetec A/S ( CPH:CHEMM ) came out with a strong set of half-year numbers that could potentially lead to...Reported Earnings • Feb 07First half 2024 earnings: EPS and revenues exceed analyst expectationsFirst half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 6.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공시 • Feb 06ChemoMetec A/S Maintains Earnings Guidance for the Year 2024ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million.Price Target Changed • Jan 12Price target decreased by 18% to kr.448Down from kr.550, the current price target is an average from 3 analysts. New target price is 18% above last closing price of kr.379. Stock is down 43% over the past year. The company is forecast to post earnings per share of kr.8.15 for next year compared to kr.10.27 last year.공시 • Dec 21ChemoMetec A/S Announces Executive ChangesChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position.분석 기사 • Dec 21Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) SharesWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 13x, you may consider...매출 및 비용 세부 내역ChemoMetec가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CPSE:CHEMM 매출, 비용 및 순이익 (DKK Millions)날짜매출순이익일반관리비연구개발비31 Dec 25493177212030 Sep 25494182210030 Jun 25496186207031 Mar 25478178199031 Dec 24460169190030 Sep 24434153186030 Jun 24408136181031 Mar 24405140176031 Dec 23402144171030 Sep 23423161166030 Jun 23444179160031 Mar 23453179166031 Dec 22461180171030 Sep 22445170166030 Jun 22428159161031 Mar 22393145147031 Dec 21358131133030 Sep 21320110125030 Jun 2128188118031 Mar 2126281108031 Dec 202437498030 Sep 202296798030 Jun 202145997031 Mar 202065499031 Dec 1919748101030 Sep 191864598030 Jun 191764294031 Mar 191583786031 Dec 181413378030 Sep 181272574030 Jun 181131869031 Mar 181071569031 Dec 171021369030 Sep 17961066030 Jun 1790764031 Mar 1788661031 Dec 1685559030 Sep 1685854030 Jun 16851050031 Mar 16801147031 Dec 15751244030 Sep 156810420양질의 수익: CHEMM는 고품질 수익을 보유하고 있습니다.이익 마진 증가: CHEMM의 현재 순 이익률 (35.9%)은 지난해 (36.8%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CHEMM의 수익은 지난 5년 동안 연평균 11.1% 증가했습니다.성장 가속화: 지난 1년간 CHEMM 의 수익 증가율(4.7%)은 5년 평균(연간 11.1%)보다 낮습니다.수익 대 산업: CHEMM의 지난 1년 수익 증가율(4.7%)은 Life Sciences 업계 평균(5.4%)을 능가하지 못했습니다.자기자본이익률높은 ROE: CHEMM의 자본 수익률(27.1%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 17:06종가2026/06/30 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChemoMetec A/S는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mads Brinkmann AndersenBerenbergKallum TitchmarshBofA Global ResearchSimon LarssonDanske Bank5명의 분석가 더 보기
Reported Earnings • Feb 06First half 2026 earnings released: EPS: kr.5.40 (vs kr.5.94 in 1H 2025)First half 2026 results: EPS: kr.5.40 (down from kr.5.94 in 1H 2025). Revenue: kr.249.0m (down 1.0% from 1H 2025). Net income: kr.94.0m (down 9.1% from 1H 2025). Profit margin: 38% (down from 41% in 1H 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 12Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: kr.10.71 (up from kr.7.83 in FY 2024). Revenue: kr.495.6m (up 22% from FY 2024). Net income: kr.186.4m (up 37% from FY 2024). Profit margin: 38% (up from 33% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
Reported Earnings • Feb 07First half 2025 earnings released: EPS: kr.5.94 (vs kr.4.05 in 1H 2024)First half 2025 results: EPS: kr.5.94 (up from kr.4.05 in 1H 2024). Revenue: kr.251.5m (up 26% from 1H 2024). Net income: kr.103.4m (up 47% from 1H 2024). Profit margin: 41% (up from 35% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
분석 기사 • Sep 18We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish EarningsDespite ChemoMetec A/S' ( CPH:CHEMM ) recent earnings report having lackluster headline numbers, the market responded...
Reported Earnings • Sep 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025
공시 • May 16ChemoMetec A/S, Annual General Meeting, Oct 08, 2026ChemoMetec A/S, Annual General Meeting, Oct 08, 2026.
Price Target Changed • May 11Price target decreased by 15% to kr.546Down from kr.640, the current price target is an average from 4 analysts. New target price is 74% above last closing price of kr.315. Stock is down 37% over the past year. The company is forecast to post earnings per share of kr.11.28 for next year compared to kr.10.71 last year.
공시 • May 06Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services.
Buy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 50% to kr.345. The fair value is estimated to be kr.432, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 59% in the next 2 years.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr.350, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 1.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.433 per share.
공시 • Mar 26ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million.
Price Target Changed • Mar 26Price target decreased by 10% to kr.691Down from kr.771, the current price target is an average from 4 analysts. New target price is 131% above last closing price of kr.299. Stock is down 41% over the past year. The company is forecast to post earnings per share of kr.11.90 for next year compared to kr.10.71 last year.
New Risk • Mar 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 43%After last week's 43% share price decline to kr.237, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years.
Buy Or Sell Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 44% to kr.416. The fair value is estimated to be kr.525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 83% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to kr.394, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 16x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.460 per share.
분석 기사 • Feb 08ChemoMetec A/S' (CPH:CHEMM) 40% Cheaper Price Remains In Tune With EarningsThe ChemoMetec A/S ( CPH:CHEMM ) share price has fared very poorly over the last month, falling by a substantial 40...
분석 기사 • Feb 07ChemoMetec A/S (CPH:CHEMM) Just Reported Earnings, And Analysts Cut Their Target PriceThere's been a major selloff in ChemoMetec A/S ( CPH:CHEMM ) shares in the week since it released its interim report...
Price Target Changed • Feb 06Price target decreased by 7.0% to kr.809Down from kr.870, the current price target is an average from 4 analysts. New target price is 87% above last closing price of kr.433. Stock is down 23% over the past year. The company is forecast to post earnings per share of kr.12.73 for next year compared to kr.10.71 last year.
Reported Earnings • Feb 06First half 2026 earnings released: EPS: kr.5.40 (vs kr.5.94 in 1H 2025)First half 2026 results: EPS: kr.5.40 (down from kr.5.94 in 1H 2025). Revenue: kr.249.0m (down 1.0% from 1H 2025). Net income: kr.94.0m (down 9.1% from 1H 2025). Profit margin: 38% (down from 41% in 1H 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Feb 06Chemometec A/S Maintains Earnings Guidance for the Year 2025ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range.
Price Target Changed • Nov 12Price target increased by 9.7% to kr.870Up from kr.793, the current price target is an average from 4 analysts. New target price is 12% above last closing price of kr.779. Stock is up 66% over the past year. The company is forecast to post earnings per share of kr.13.80 for next year compared to kr.10.71 last year.
Recent Insider Transactions • Nov 10Chief Executive Officer recently bought kr.1.0m worth of stockOn the 7th of November, Martin Behrens bought around 1k shares on-market at roughly kr.684 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months.
분석 기사 • Oct 31Earnings Tell The Story For ChemoMetec A/S (CPH:CHEMM) As Its Stock Soars 27%Despite an already strong run, ChemoMetec A/S ( CPH:CHEMM ) shares have been powering on, with a gain of 27% in the...
공시 • Oct 28ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26.
Price Target Changed • Oct 27Price target increased by 17% to kr.793Up from kr.677, the current price target is an average from 3 analysts. New target price is 9.4% above last closing price of kr.725. Stock is up 78% over the past year. The company is forecast to post earnings per share of kr.13.05 for next year compared to kr.10.71 last year.
Buy Or Sell Opportunity • Oct 27Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to kr.725. The fair value is estimated to be kr.585, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
공시 • Oct 10ChemoMetec A/S Approves to Distribute DividendChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1.
Declared Dividend • Oct 03Dividend increased to kr.7.00Dividend of kr.7.00 is 75% higher than last year. Ex-date: 10th October 2025 Payment date: 14th October 2025 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (85% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Buy Or Sell Opportunity • Oct 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to kr.654. The fair value is estimated to be kr.545, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
분석 기사 • Oct 01Calculating The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)Key Insights The projected fair value for ChemoMetec is kr.554 based on 2 Stage Free Cash Flow to Equity Current share...
Valuation Update With 7 Day Price Move • Sep 18Investor sentiment improves as stock rises 20%After last week's 20% share price gain to kr.653, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 15x in the Life Sciences industry in Europe. Total returns to shareholders of 8.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.553 per share.
공시 • Sep 18ChemoMetec A/S, Annual General Meeting, Oct 09, 2025ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark
분석 기사 • Sep 16ChemoMetec A/S (CPH:CHEMM) Looks Just Right With A 26% Price JumpChemoMetec A/S ( CPH:CHEMM ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
Price Target Changed • Sep 15Price target increased by 8.6% to kr.677Up from kr.623, the current price target is an average from 3 analysts. New target price is 7.2% above last closing price of kr.632. Stock is up 52% over the past year. The company is forecast to post earnings per share of kr.13.07 for next year compared to kr.10.71 last year.
분석 기사 • Sep 15ChemoMetec A/S (CPH:CHEMM) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?It's been a pretty great week for ChemoMetec A/S ( CPH:CHEMM ) shareholders, with its shares surging 12% to kr.610 in...
공시 • Sep 13+ 3 more updatesChemometec A/S Provides Earnings Guidance for the Financial Year 2025/26ChemoMetec A/S provided earnings guidance for the financial year 2025/26. For the period, ChemoMetec expects revenue in the range of DKK 545 million-565 million (2024/25: DKK 495.6 million).
Reported Earnings • Sep 12Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: kr.10.71 (up from kr.7.83 in FY 2024). Revenue: kr.495.6m (up 22% from FY 2024). Net income: kr.186.4m (up 37% from FY 2024). Profit margin: 38% (up from 33% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
Buy Or Sell Opportunity • Sep 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.1% to kr.562. The fair value is estimated to be kr.466, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 48% in the next 2 years.
분석 기사 • Jul 07ChemoMetec A/S' (CPH:CHEMM) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 15x, you may consider...
New Risk • Jun 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Danish stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Jun 11At kr.554, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?While ChemoMetec A/S ( CPH:CHEMM ) might not have the largest market cap around , it led the CPSE gainers with a...
분석 기사 • Apr 06Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is UnlikelyWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 13x, you may consider...
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to kr.424, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.313 per share.
분석 기사 • Feb 08ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent ResultsAs you might know, ChemoMetec A/S ( CPH:CHEMM ) recently reported its half-year numbers. Overall the results were a...
Reported Earnings • Feb 07First half 2025 earnings released: EPS: kr.5.94 (vs kr.4.05 in 1H 2024)First half 2025 results: EPS: kr.5.94 (up from kr.4.05 in 1H 2024). Revenue: kr.251.5m (up 26% from 1H 2024). Net income: kr.103.4m (up 47% from 1H 2024). Profit margin: 41% (up from 35% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 06Price target increased by 12% to kr.613Up from kr.545, the current price target is an average from 2 analysts. New target price is 7.8% above last closing price of kr.568. Stock is up 18% over the past year. The company is forecast to post earnings per share of kr.11.51 for next year compared to kr.7.83 last year.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr.560, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.351 per share.
공시 • Jan 10Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial YearChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance.
분석 기사 • Dec 12What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?ChemoMetec A/S ( CPH:CHEMM ), might not be a large cap stock, but it saw a significant share price rise of 42% in the...
공시 • Dec 04ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance.
Recent Insider Transactions • Nov 12Deputy Chairman & Senior Advisor recently bought kr.3.2m worth of stockOn the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly kr.456 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of kr.3.5m worth in shares.
Price Target Changed • Nov 11Price target increased by 15% to kr.505Up from kr.438, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of kr.504. Stock is up 55% over the past year. The company is forecast to post earnings per share of kr.10.06 for next year compared to kr.7.83 last year.
Major Estimate Revision • Nov 10Consensus EPS estimates increase by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from kr.9.26 to kr.10.24. Revenue forecast steady at kr.460.2m. Net income forecast to grow 31% next year vs 29% growth forecast for Life Sciences industry in Denmark. Consensus price target of kr.438 unchanged from last update. Share price rose 19% to kr.484 over the past week.
분석 기사 • Nov 09ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than ExpectedThe ChemoMetec A/S ( CPH:CHEMM ) share price has done very well over the last month, posting an excellent gain of 32...
New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (21% accrual ratio).
공시 • Nov 08ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million.
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr.484, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.266 per share.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Oct 23ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date. ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024.
공시 • Oct 17ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance.
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to kr.438, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.239 per share.
공시 • Oct 11ChemoMetec A/S Approves DividendChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1.
Upcoming Dividend • Oct 04Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of Danish dividend payers (5.8%). Higher than average of industry peers (0.7%).
공시 • Sep 21ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. The transaction is subject to consummation of due diligence investigation.
분석 기사 • Sep 18We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish EarningsDespite ChemoMetec A/S' ( CPH:CHEMM ) recent earnings report having lackluster headline numbers, the market responded...
Declared Dividend • Sep 15Dividend of kr.4.00 announcedShareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 0.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Price Target Changed • Sep 13Price target increased by 8.0% to kr.473Up from kr.438, the current price target is an average from 2 analysts. New target price is 10.0% above last closing price of kr.430. Stock is up 20% over the past year. The company is forecast to post earnings per share of kr.9.05 for next year compared to kr.7.83 last year.
Reported Earnings • Sep 12Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공시 • Sep 12ChemoMetec A/S provides earnings guidance for the year 2024/25ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year.
Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr.429, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.261 per share.
공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025
분석 기사 • Jul 29What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling YouThe ChemoMetec A/S ( CPH:CHEMM ) share price has done very well over the last month, posting an excellent gain of 27...
분석 기사 • Jul 29Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%ChemoMetec A/S ( CPH:CHEMM ) shareholders have had their patience rewarded with a 27% share price jump in the last...
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr.352, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.238 per share.
분석 기사 • Jul 03What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?ChemoMetec A/S ( CPH:CHEMM ), is not the largest company out there, but it received a lot of attention from a...
공시 • May 25ChemoMetec A/S Announces CFO ChangesThe board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec.
Recent Insider Transactions • May 16Independent Director recently bought kr.450k worth of stockOn the 13th of May, Peter Reich bought around 1k shares on-market at roughly kr.310 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr.751k more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • May 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr.366, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.220 per share.
Buy Or Sell Opportunity • Apr 26Now 20% overvaluedOver the last 90 days, the stock has fallen 30% to kr.287. The fair value is estimated to be kr.238, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.
Price Target Changed • Apr 16Price target increased by 14% to kr.513Up from kr.448, the current price target is an average from 2 analysts. New target price is 65% above last closing price of kr.310. Stock is down 11% over the past year. The company is forecast to post earnings per share of kr.7.69 for next year compared to kr.10.27 last year.
Buy Or Sell Opportunity • Apr 15Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to kr.298. The fair value is estimated to be kr.246, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 33% in the next 2 years.
분석 기사 • Apr 15Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%ChemoMetec A/S ( CPH:CHEMM ) shareholders won't be pleased to see that the share price has had a very rough month...
공시 • Apr 13ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to kr.310, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.246 per share.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr.444, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.245 per share.
공시 • Mar 13ChemoMetec A/S Announces CEO ChangesThe Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec.
분석 기사 • Mar 01What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling YouDespite an already strong run, ChemoMetec A/S ( CPH:CHEMM ) shares have been powering on, with a gain of 30% in the...
분석 기사 • Mar 01What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?ChemoMetec A/S ( CPH:CHEMM ), might not be a large cap stock, but it led the CPSE gainers with a relatively large price...
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 30%After last week's 30% share price gain to kr.462, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.246 per share.
분석 기사 • Feb 08Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsA week ago, ChemoMetec A/S ( CPH:CHEMM ) came out with a strong set of half-year numbers that could potentially lead to...
Reported Earnings • Feb 07First half 2024 earnings: EPS and revenues exceed analyst expectationsFirst half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 6.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공시 • Feb 06ChemoMetec A/S Maintains Earnings Guidance for the Year 2024ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million.
Price Target Changed • Jan 12Price target decreased by 18% to kr.448Down from kr.550, the current price target is an average from 3 analysts. New target price is 18% above last closing price of kr.379. Stock is down 43% over the past year. The company is forecast to post earnings per share of kr.8.15 for next year compared to kr.10.27 last year.
공시 • Dec 21ChemoMetec A/S Announces Executive ChangesChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position.
분석 기사 • Dec 21Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) SharesWhen close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 13x, you may consider...